Centennial Growth Equities acquires exclusive rights to TNG and supplements, exits shell status

NIKA PHARMACEUTICALS, INC

Acquired 15-year exclusive rights to manufacture and distribute Thymus Nuclear Glycoprotein (TNG) from VITAL FE.
Also acquired 15-year rights to dietary supplements Palmcarotilen and Fiziolong from MICAR 11.
Consideration: 8M preferred shares (to Dimitar Savov) for TNG rights; 2M preferred shares for supplement rights.
Preferred shares granted 1,000 votes each, giving Savov ~10B votes; company no longer a shell company.
Dimitar Savov is CEO/Director and is the owner of both VITAL (70%) and MICAR (100%).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.